Innoviva, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INVA research report →
About the company
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA.
- CEO
- Pavel Raifeld
- IPO
- 2004
- Employees
- 127
- HQ
- Burlingame, CA, US
Price Chart
- Market Cap
- $1.65B
- P/E
- 3.18
- P/S
- 3.88
- P/B
- 1.23
- EV/EBITDA
- 2.15
- Div Yield
- 0.00%
- Gross Margin
- 76.20%
- Op Margin
- 14.85%
- Net Margin
- 118.91%
- ROE
- 47.59%
- ROIC
- 2.93%
- Revenue
- $425.13M · 18.52%
- Net Income
- $271.17M · 1059.22%
- EPS
- $4.02 · 986.49%
- Op Income
- $163.75M
- FCF YoY
- -1.06%
- 52W High
- $25.15
- 52W Low
- $16.52
- 50D MA
- $22.63
- 200D MA
- $21.18
- Beta
- 0.35
- Avg Volume
- 776.89K
Get TickerSpark's AI analysis on INVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Basso Stephen | other | 1,123 |
| May 20, 26 | Basso Stephen | other | 559 |
| May 15, 26 | Raifeld Pavel | other | 1,123 |
| May 20, 26 | Raifeld Pavel | other | 1,130 |
| May 20, 26 | Zhen Marianne | other | 1,127 |
| May 18, 26 | Linden Josephine | other | 9,461 |
| May 18, 26 | Linden Josephine | other | 9,166 |
| May 18, 26 | Linden Josephine | other | 5,733 |
| May 18, 26 | Linden Josephine | other | 0 |
| May 4, 26 | Raifeld Pavel | other | 312,500 |
Our INVA coverage
Recent articles, reports, and earnings notes.
No research on INVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INVA report →Similar companies
Peers in the same neighborhood.